浩欧博：MM09舌下喷雾剂III期临床试验完成首批受试者入组

Core Viewpoint - The company has successfully completed the initial enrollment and administration of the desensitization drug MM09 sublingual spray in a Phase III clinical trial, in collaboration with Inmunotek [1] Group 1: Company Developments - The company received notification from its wholly-owned subsidiary, Shanghai Haooubo Biopharmaceutical Co., Ltd., regarding the successful completion of the first batch of subject enrollment for the MM09 sublingual spray [1] - The company is positioned as a leading entity in the field of allergy diagnosis and is expanding its business into allergen desensitization treatment, filling a domestic gap in this area [1] Group 2: Industry Impact - The development of the MM09 sublingual spray is expected to promote the company's "diagnosis and treatment integration," enhancing the synergy between allergy diagnosis and desensitization treatment [1] - This initiative aims to provide a more convenient and efficient desensitization treatment solution for domestic allergy patients [1]